🎉 M&A multiples are live!
Check it out!

Abeona Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Abeona Therapeutics and similar public comparables like Pharming, Galapagos, and Julphar.

Abeona Therapeutics Overview

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.


Founded

1974

HQ

United States of America
Employees

136

Financials

LTM Revenue $11.2M

LTM EBITDA n/a

EV

$167M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Abeona Therapeutics Financials

Abeona Therapeutics has a last 12-month revenue of $11.2M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Abeona Therapeutics achieved revenue of n/a and an EBITDA of -$56.6M.

Abeona Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Abeona Therapeutics valuation multiples based on analyst estimates

Abeona Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $3.5M n/a XXX XXX XXX
Gross Profit $1.0M $1.9M XXX XXX XXX
Gross Margin 28% Infinity% XXX XXX XXX
EBITDA -$50.6M -$56.6M XXX XXX XXX
EBITDA Margin -1445% -Infinity% XXX XXX XXX
Net Profit -$39.7M -$54.2M XXX XXX XXX
Net Margin -1134% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Abeona Therapeutics Stock Performance

As of April 15, 2025, Abeona Therapeutics's stock price is $5.

Abeona Therapeutics has current market cap of $242M, and EV of $167M.

See Abeona Therapeutics trading valuation data

Abeona Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$167M $242M XXX XXX XXX XXX $-1.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Abeona Therapeutics Valuation Multiples

As of April 15, 2025, Abeona Therapeutics has market cap of $242M and EV of $167M.

Abeona Therapeutics's trades at 15.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Abeona Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Abeona Therapeutics and 10K+ public comps

Abeona Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $167M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.9x XXX XXX XXX
P/E -3.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Abeona Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Abeona Therapeutics Valuation Multiples

Abeona Therapeutics's NTM/LTM revenue growth is 361%

Abeona Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Abeona Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Abeona Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Abeona Therapeutics and other 10K+ public comps

Abeona Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Abeona Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Abeona Therapeutics M&A and Investment Activity

Abeona Therapeutics acquired  XXX companies to date.

Last acquisition by Abeona Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Abeona Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Abeona Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Abeona Therapeutics

When was Abeona Therapeutics founded? Abeona Therapeutics was founded in 1974.
Where is Abeona Therapeutics headquartered? Abeona Therapeutics is headquartered in United States of America.
How many employees does Abeona Therapeutics have? As of today, Abeona Therapeutics has 136 employees.
Who is the CEO of Abeona Therapeutics? Abeona Therapeutics's CEO is Mr. Vishwas Seshadri.
Is Abeona Therapeutics publicy listed? Yes, Abeona Therapeutics is a public company listed on NAS.
What is the stock symbol of Abeona Therapeutics? Abeona Therapeutics trades under ABEO ticker.
When did Abeona Therapeutics go public? Abeona Therapeutics went public in 1980.
Who are competitors of Abeona Therapeutics? Similar companies to Abeona Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Abeona Therapeutics? Abeona Therapeutics's current market cap is $242M
What is the current revenue of Abeona Therapeutics? Abeona Therapeutics's last 12-month revenue is $11.2M.
What is the current EV/Revenue multiple of Abeona Therapeutics? Current revenue multiple of Abeona Therapeutics is 15.0x.
Is Abeona Therapeutics profitable? Yes, Abeona Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.